ClinicalTrials.gg
RecruitingNCT06855771Updated Sep 18, 2026

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

A Phase 2 interventional study of BMS-986504 and Izalontamab Brengitecan in Carcinoma, Non-Small-Cell Lung, sponsored by Bristol-Myers Squibb. Recruiting at 67 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Planned enrollment
52nd of 107
182 · median 169
Started
2025
with 9 others
Phase 2
32 of 131
3 open now
Primary completion
2028-12
later than 22 of 34 live
Registered
114th of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 52nd largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2025, is one of 32 in phase 2, reaches primary completion later than 22 of the 34 other live ones, and was the 114th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation.
  • Advanced or NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).
  • At least 1 as per v1.1.
  • Documented radiographic disease progression on or after the most recent .
  • (ECOG) performance status of 0-1.
  • Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
  • Capability to swallow tablets intact (without chewing or crushing).
  • For combination arms

    1. Participants must have documented evidence of EGFR status.
    2. Participants with EGFR mutant or wild type NSCLC are allowed.

Exclusion criteria

Exclusion Criteria

  • Active or carcinomatous meningitis.
  • History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
  • Prior treatment with a PRMT5 or MAT2A inhibitor.
  • Known severe to study treatment and/or any of its .
  • For combination arms

    a. Prior therapy with iza-bren or any other antibody and/or ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload, except amivantamab.

  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Arm A: BMS-986504 Dose 1

    Drug: BMS-986504

  • Experimental
    Arm B: BMS-986504 Dose 2

    Drug: BMS-986504

  • Experimental
    Arm C: BMS-986504 Dose 1 + Izalontamab Brengitecan

    Drug: BMS-986504 · Drug: Izalontamab Brengitecan

  • Experimental
    Arm D: BMS-986504 Dose 2 + Izalontamab Brengitecan

    Drug: BMS-986504 · Drug: Izalontamab Brengitecan

Interventions

  • Specified dose on specified days

    Also known as: MRTX1719, Navlimetostat

  • Specified dose on specified days

    Also known as: BMS-986507, BL-BO1D1, Iza-bren

06

What researchers measure

Primary outcomes

  1. Number of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    OR is defined as confirmed complete response (CR) or partial response (PR)

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  2. Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteria

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  3. Number of participants with adverse events (AE)

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  4. Number of participants with Serious AEs (SAEs)

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  5. Number of participants with treatment related AEs

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  6. Number of participants with treatment related SAEs

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  7. Number of participants with AEs leading to study treatment discontinuation

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  8. Number of participants with AEs leading to death

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

  9. Number of participants with laboratory abnormalities

    Arm C and Arm D

    Time frame: Up to 28 days after the last dose of study treatment

Secondary outcomes

  1. Number of participants who achieve disease control (DC) as assessed by RECIST v1.1

    DC is defined as Best Overall Response (BOR) of confirmed CR, confirmed PR, or stable disease (SD)

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  2. Number of participants who achieve clinical benefit (CB) as assessed by RECIST v1.1

    CB is defined as BOR of confirmed CR, confirmed PR, or SD for at least 6 months after start of treatment

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  3. Duration of response (DOR) as assessed by RECIST v1.1

    DOR is defined as the time between the date of the first documentation of objective tumor response (confirmed CR or PR) and the date of disease progression or to death from any cause (whichever occurs first)

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  4. Progression-free survival (PFS) as assessed by RECIST v1.1

    PFS is defined as the time between randomization and the date of disease progression or death from any cause (whichever occurs first)

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  5. Time to objective response (TTOR) as assessed by RECIST v1.1

    TTOR is defined as the time between randomization to the date of the first documentation of objective tumor response (confirmed CR or PR)

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  6. Number of participants with adverse events (AE)

    Time frame: Up to 28 days after the last dose of study treatment

  7. Number of participants with Serious AEs (SAEs)

    Time frame: Up to 28 days after the last dose of study treatment

  8. Number of participants with AEs leading to dose interruption, reduction, or discontinuation

    Time frame: Up to 28 days after the last dose of study treatment

  9. Number of deaths

    Time frame: Up to 28 days after the last dose of study treatment

  10. Number of participants who achieve Objective Response (OR) as assessed by RECIST v1.1

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  11. Overall Survival (OS)

    OS is defined as the time between the randomization/the start of treatment to death due to any cause

    Time frame: Up to 3 years after the last participant's last dose of study treatment

  12. Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) total score and symptom score

    Time frame: Up to 28 days after the last dose of study treatment

  13. Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Function Global Health Status score

    Time frame: Up to 28 days after the last dose of study treatment

  14. Change from baseline in cancer-related symptoms and health-related quality of life as assessed by the EORTC-QLQ-F17 quality-of-life (QoL) functional scale score

    Time frame: Up to 28 days after the last dose of study treatment

07

Study locations

65 of 67 sites recruiting
  • Local Institution - 0088
    Anchorage, Alaska 99508, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Pasi Janne, Site 0090 · Contact617-632-6036
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Hirva Mamdani, Site 0100 · Contact909-525-0093
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Anjali Rohatgi, Site 0104 · Contact314-747-1171
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Kathryn Arbour, Site 0018 · Contact646-608-3792
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
    Recruiting
    • Nashat Gabrail, Site 0091 · Contact330-417-8231
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
    Recruiting
    • Rachel Sanborn, Site 0098 · Contact503-215-5696
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Jeremy Cetnar, Site 0103 · Contact503-494-3840
  • Fred Hutchison Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Lei Deng, Site 0078 · Contact206-606-4801
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Jonathan Thompson, Site 0084 · Contact414-805-4600
  • GenesisCare - Campbelltown
    Campbelltown, New South Wales 2560, Australia
    Recruiting
    • Jessica Smith, Site 0057 · Contact+61 2 4632 5500
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
    Recruiting
    • Steven Kao, Site 0059 · Contact+61 2 85140594
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
    Recruiting
    • Wen Xu, Site 0058 · Contact(+61) 731762111
  • Local Institution - 0097
    Adelaide, South Australia 5000, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Beijing Chest Hospital,Capital Medical University
    Beijing, Beijing Municipality 101149, China
    Recruiting
    • Zhe Liu, Site 0039 · Contact010-8909303
  • The First Affiliated hospital of Xiamen University
    Xiamen, Fujian 361003, China
    Recruiting
    • Feng Ye, Site 0055 · Contact8613860458889
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530201, China
    Recruiting
    • Wenhua Zhao, Site 0050 · Contact13878873120
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Longhua Sun, Site 0043 · Contact8613698091288
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Ligang Xing, Site 0054 · Contact86-15553181309
  • LinYi Cancer Hospital
    Linyi, Shandong 276001, China
    Recruiting
    • Jianhua Shi, Site 0044 · Contact+8615963998868
  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Enguo Chen, Site 0049 · Contact13588706779
  • Taizhou Hospital of Zhejiang Province
    Linhai, Zhejiang 317000, China
    Recruiting
    • Dongqing LV, Site 0053 · Contact13867622009
  • Chu Grenoble Alpes
    La Tronche, Isère 38700, France
    Recruiting
    • Denis Moro-Sibilot, Site 0015 · Contact33476765467
  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
    Saint-Herblain, Loire-Atlantique 44800, France
    Recruiting
    • Elvire Pons-Tostivint, Site 0012 · Contact+33676133810
  • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
    Recruiting
    • Bertrand Mennecier, Site 0095 · Contact33383154653
  • Hospices Civils de Lyon - Hopital Louis Pradel
    Bron, Rhône 69677, France
    Recruiting
    • Michael Duruisseaux, Site 0041 · Contact33427857700
  • Hopitaux Universitaires Paris Centre-Hopital Cochin
    Paris, 75014, France
    Recruiting
    • Marie Wislez, Site 0013 · Contact33158413091
  • Institut Curie
    Paris, 75248, France
    Recruiting
    • nicolas girard, Site 0107 · Contact+33624456290
  • Hôpital Tenon
    Paris, 75970, France
    Recruiting
    • Jacques Cadranel, Site 0027 · Contact33156016531
  • Groupe hospitalier Paris saint Joseph
    Paris, Île-de-France Region 75014, France
    Recruiting
    • Carole Helissey-Danis, Site 0096 · Contact33330143985319
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
    München, Bavaria 81377, Germany
    Recruiting
    • Diego Kauffmann-Guerrero, Site 0068 · Contact4989440052590
  • Universitätsklinikum Frankfurt Goethe-Universität
    Frankfurt am Main, Hesse 60590, Germany
    Recruiting
    • Fabian Acker, Site 0070 · Contact0000
  • Krankenhaus Martha-Maria Halle-Dölau
    Halle, Saxony-Anhalt 06120, Germany
    Recruiting
    • Miriam Moeller, Site 0066 · Contact00493455591440
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
    Recruiting
    • Juergen Wolf, Site 0067 · Contact+4922147889050
  • Universitaetsklinikum Wuerzburg
    Würzburg, 97080, Germany
    Recruiting
    • Elisabeth Goebeler, Site 0065 · Contact4993120140155
  • AOU della Campania Luigi Vanvitelli
    Naples, Campania 80131, Italy
    Recruiting
    • Carminia Maria Della Corte, Site 0026 · Contact3929160541
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    Naples, Campania 80131, Italy
    Recruiting
    • Alessandro Morabito, Site 0020 · Contact390817770291
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
    Recruiting
    • Diego Cortinovis, Site 0025 · Contact390392333683
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, Milano 20162, Italy
    Recruiting
    • Giulio Cerea, Site 0022 · Contact390264442291
  • Istituto Oncologico Veneto IRCCS
    Padova, Veneto 35128, Italy
    Recruiting
    • Giulia Pasello, Site 0023 · Contact39498215620
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
    Bologna, 40138, Italy
    Recruiting
    • Francesco Gelsomino, Site 0024 · Contact+390512142203
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Recruiting
    • Claudia Proto, Site 0019 · Contact390223903829
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
    Recruiting
    • Hibiki Udagawa, Site 0092 · Contact81471331111
  • Sendai Kousei Hospital
    Sendai, Miyagi 9810914, Japan
    Recruiting
    • Shunichi Sugawara, Site 0094 · Contact81227288000
  • Kansai Medical University Hospital
    Hirakata, Osaka 573-1191, Japan
    Recruiting
    • Takayasu Kurata, Site 0093 · Contact81728042503
  • Mazowiecki Szpital Onkologiczny
    Wieliszew, Masovian Voivodeship 05-135, Poland
    Recruiting
    • Renata Biernacka, Site 0060 · Contact509120229
  • Szpital Specjalistyczny w Prabutach Spolka z o.o.
    Prabuty, 82-550, Poland
    Recruiting
    • Anna Lowczak, Site 0064 · Contact+48503022396
  • Institutul Oncologic Bucuresti "Prof. Dr. Alexandru Trestioreanu"
    Bucharest, Bucharest 022338, Romania
    Recruiting
    • Aurelia Alexandru, Site 0029 · Contact40723289606
  • SC Radiotherapy Center Cluj SRL
    Florești, Cluj 407280, Romania
    Recruiting
    • Andrei Ungureanu, Site 0036 · Contact40742206212
  • Centrul de Oncologie "Sfântul Nectarie"
    Craiova, Dolj 200542, Romania
    Recruiting
    • Michael Schenker, Site 0031 · Contact40727774974
  • Centrul de Diagnostic si Tratament Provita
    Bucharest, 020335, Romania
    Recruiting
    • Mircea Dediu, Site 0040 · Contact0040744432443
  • Institutul Oncologic Cluj
    Cluj-Napoca, 400015, Romania
    Recruiting
    • Tudor Ciuleanu, Site 0034 · Contact40745646368
  • S.C. Centrul de Oncologie Euroclinic S.R.L.
    Iași, 700106, Romania
    Recruiting
    • Constantin Volovat, Site 0030 · Contact40746110096
  • Institutul Regional de Oncologie
    Iași, 700483, Romania
    Recruiting
    • Dana Clement, Site 0032 · Contact40744692062
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Enriqueta Felip Font, Site 0074 · Contact34932746077
  • Institut Català d'Oncologia - L'Hospitalet
    Hospitalet, Barcelona [Barcelona] 08907, Spain
    Recruiting
    • Ernest Nadal Alforja, Site 0073 · Contact34932607283
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad de 28034, Spain
    Recruiting
    • Maria Eugenia Olmedo Garcia, Site 0077 · Contact34913368263
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
    Recruiting
    • Luis Paz-Ares Rodriguez, Site 0071 · Contact+34913908546
  • Hospital Universitario La Paz
    Madrid, Madrid, Comunidad de 28046, Spain
    Recruiting
    • Javier de Castro Carpeno, Site 0076 · Contact34917277516
  • H.R.U Málaga - Hospital General
    Málaga, 29011, Spain
    Recruiting
    • Manuel Cobo-Dols, Site 0075 · Contact00349422033350000
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
    • Reyes Bernabe Caro, Site 0089 · Contact34955015273
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
    • Oscar Juan Vidal, Site 0072 · Contact34961245877
  • Karolinska Universitetssjukhuset Solna
    Solna, Stockholms Län [se-01] 171 64, Sweden
    Recruiting
    • Luigi DePetris, Site 0002 · Contact45 08-123 79517
  • Sahlgrenska Universitetssjukhuset
    Gothenburg, Västra Götalands Län [se-14] 413 45, Sweden
    Recruiting
    • Andreas Hallqvist, Site 0003 · Contact+46735-985411
  • Queen Elizabeth Hospital Birmingham
    Birmingham, England B15 2TH, United Kingdom
    Recruiting
    • Gary Middleton, Site 0069 · Contact+44 121 3718783
  • Sarah Cannon Research Institute UK
    London, London, City of w1g 6ad, United Kingdom
    Recruiting
    • Elisa Fontana, Site 0008 · Contact+44 (0) 203 219 5234
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
    Recruiting
    • Alastair Greystoke, Site 0004 · Contact+44 (0)191 213 8450
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 39 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 4, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Dec 29, 2028
CompletionEst.
Dec 30, 2031
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06855771
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Sep 9, 2025
Primary completion
Dec 29, 2028 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Sep 18, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navlimetostat

Start the discussion